Novo Nordisk partners with AWS to accelerate AI-driven drug discovery - NVO News | RalliesNovo Nordisk partners with AWS to accelerate AI-driven drug discovery
N
NVO• Novo Nordisk and AWS expand AI partnership
- Novo Nordisk struck a strategic partnership with AWS to accelerate drug discovery using agentic AI and cloud technology.
- A new co-innovation hub in London will embed AWS engineers and scientists with Novo Nordisk R&D to shorten timelines from target to first human dose.
- AWS becomes Novo Nordisk’s preferred cloud provider and strategic AI partner as the drugmaker modernizes its technology infrastructure.
- The companies cited early gains, including shorter clinical documentation time and AI tools rolled out to more than 25,000 employees.
SCKT
•
